Partillion Bioscience’s Post

Really fundamental and cutting-edge science article in JCR by my AstraZeneca #AdvancedDrugDelivery and Industry Colleagues Mark Jackman, Weimin Li, Aaron Smith, David Workman, Kevin Treacher, Adam Corrigan, Fadi Adnan Abdulrazzaq, Silvia Sonzini, Zahid Nazir, Jayne Lawrence, Najet Mahmoudi, David Grant, Jonathan Counsell, Jonathan Cairns, Douglas Ferguson, Eva Lenz, Saif Baquain, Christine Madla, Sally van Pelt, Jennifer Moss, Alison Peter, Sanyogitta Puri, Marianne Ashford, Mariarosa Mazza! The article outlines key #advancedcharacterization needed to design successful #nanomedicines by defining #CriticalQualityAttributes from the get-go. The link between nanoparticle characteristics and in vivo performance is outlined using techniques such as transmission electron microscopy, small-angle x-ray and neutron scattering, NMR and hard-energy x-ray photoelectron spectroscopy. A worthwhile and must read to ensure successful design of novel nanoparticles! https://lnkd.in/egndEpdK

Virtual conference   November 11, 2024 – November 13, 2024 Organized by Shanghai Institute for Advanced Immunochemical Studies(SIAIS), iHuman Institute, School of Life Science and Technology (SLST), School of Biomedical Engineering (BME), Shanghai Clinical Research and Trial Center, National Center for Protein Science •Shanghai (NCPSS), Nature Communications The aim of this conference is to be a premier international forum that provides direction on the latest developments through keynote presentations by high-level experts in the field of drug discovery and development, and to provide a stage for young scientists aspiring to professorships in the near future to exchange excellent research. The focus of the conference is on cutting-edge research in the field of drug discovery and development, both in terms of new approaches and technologies as well as new drugs in drug discovery and development. For technologies, we will particularly focus on artificial intelligence, degradation technologies for design such as PROTACs and molecular glues, gene editing, DNA-encoded compound libraries, nucleic acid drugs, etc.; for drugs, we will emphasize the discovery of first-in-class targets and new molecules. The conference will provide networking opportunities with the peers to help establish connections for early career scientists to meet a diverse mix of researchers. Session details: 1. Drug target identification and validation 2. Advanced Lead Discovery and Generation Technologies 3. Emerging New Drug Modalities

🚀 Let's connect at the prestigious 26th INTERPHEX Week Tokyo. 📍 Venue: Tokyo Big Sight, Japan 📅 Save the Date: June 26th-28th, 2024 🎨 Booth No: 48-6 (East Hall 6) 👉 Explore with us: 1⃣ Uncover the advantages of our revolutionary fully dissolvable porous 3D microcarrier, paving the way for mass production of adherent cell culture. 2⃣ Dive into the process development and the latest clinical progress of our state-of-the-art, fully automated, and closed production system designed for the production of 10 Billion Mesenchymal Stem Cells, leveraging dissolvable microcarriers. 3⃣ Discover the diverse applications of dissolvable microcarriers in virus production, revolutionizing the landscape of biologics manufacturing.

kinetic assays and live cell assays...

🔬 Uncover the Importance of Kinetic Assays in Drug Discovery with Arctoris! 🔬 Kinetic assays are vital in any drug discovery program. By understanding binding kinetics and target engagement you can differentiate between molecules with similar IC50s to ensure you are selecting the right lead or candidate molecule. Arctoris can support your pipeline by offering:  👉 Biophysical kinetic screening to give crucial insights into molecular interactions  👉 Target engagement, both in vitro and in live cells, to  illuminate the effectiveness of compounds 👉 Real-time physiological responses with live cell imaging and other in cell kinetic assays including viability, cytotoxicity and HiBiT to better understand mode of action. Experience the power of kinetic assays with Arctoris. Let's advance drug discovery together! Check the comments for more information. 💡#KineticAssays #DrugDiscovery #ExperimentDesign #Biotech🚀

How you can get more data depth and understanding by running your experiments kinetically? 👉 Understand molecular dynamics and binding affinities & modes 👉 Identify intermediate or transient states 👉 Understand how different variables interact 👉 Assess the impact in a more physiological setting

Interested in how cellular target engagement is transforming #drugdiscovery? Explore the capabilities of NanoBRET® Target Engagement Technology in an expert interview with Amy Landreman, Senior Product Manager at Promega. Discover how this advanced technology combines the precision of biochemical assays with the complexities of cellular contexts to revolutionize drug discovery. Don’t miss these essential insights—dive in now: https://bit.ly/3X5oP1U

⭐Publication Spotlight⭐     Dueñas ME, Peltier-Heap RE, Leveridge M, Annan RS, Büttner FH & Trost M. Advances in high-throughput mass spectrometry in drug discovery. EMBO Mol Med 15: e14850 (2023)  https://lnkd.in/dM78wG-V    In this review article, Dueñas et al. make the case for high-throughput mass spectrometry as a uniquely powerful drug discovery tool, describing recent technological advances that have made these assays "cheaper, faster, and more physiologically relevant" than competitors. The authors provide a clear and cogent overview of MS technologies and highlight the RapidFire-MS platform (invented by our team!) as a key innovation in the development of high-throughput mass spectrometry,      We were also excited by their discussion of Affinity Selection Mass Spectrometry (ASMS), one of Momentum's cornerstone assays. The authors establish the value of ASMS as a label-free, direct detection screening approach that requires minimal assay development and "can accommodate targets where very little knowledge of protein function or structure exists." They also discuss potential challenges of this approach – reminding us how fortunate we are that Momentum's team has the deep knowledge and experience necessary to perform these assays successfully and efficiently.      Check out the link above to read the full article! And if you think that high-throughput mass spectrometry could be the answer to your assay challenges, contact us to learn more: https://lnkd.in/e6GFCEvW 

Check out my recent Q&A interview!

I am extremely happy to share that our work, "Enhanced Drug Delivery via Localization-Enabled Relaying in Molecular Communication Nanonetworks," has been accepted for presentation at the ACM NanoCom 2024 conference! I extend a sincere thank you to Ethungshan Shitiri for his constant support and collaboration. Working together over the past two years has been an enriching experience! Abstract: Intra-body nanonetworks are promising for advancing healthcare, particularly through molecular communication (MC) systems. Here, we introduce a localization-enabled relaying mechanism designed to enhance the performance of targeted drug delivery (TDD) systems. Our approach involves randomly positioned drug-loaded nanomachines (DgNs) that self-organize into clusters based on localization signals from a nano-controller. This network of relays, established without explicit proximity knowledge, significantly improves drug delivery efficiency. Through rigorous numerical evaluations, we demonstrate a 17% enhancement in drug delivery performance over the baseline methods. Crucially, we identify an optimal cluster threshold that maximizes the combined channel impulse response (CIR) between DgNs and the infected tissue. This finding highlights the critical balance between relay link quantity and CIR quality in achieving optimal drug delivery. Our findings pave the way for future investigations into CIR-based relay selection and the influence of variables such as drug molecule lifespan, obstruction probabilities, and flow dynamics.